FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200724207> ?p ?o ?g. }

• W3200724207 endingPage "4573" @default.
• W3200724207 startingPage "4565" @default.
• W3200724207 abstract "The authors hypothesized that patients developing immune-related adverse events (irAEs) while receiving immune checkpoint inhibition (ICI) for recurrent/metastatic head and neck cancer (HNC) would have improved oncologic outcomes.Patients with recurrent/metastatic HNC received ICI at 2 centers. Univariate and multivariate logistic regression, Kaplan-Meier methods, and Cox proportional hazards regression were used to associate the irAE status with the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in cohort 1 (n = 108). These outcomes were also analyzed in an independent cohort of patients receiving ICI (cohort 2; 47 evaluable for irAEs).The median follow-up was 8.4 months for patients treated in cohort 1. Sixty irAEs occurred in 49 of 108 patients with 5 grade 3 or higher irAEs (10.2%). ORR was higher for irAE+ patients (30.6%) in comparison with irAE- patients (12.3%; P = .02). The median PFS was 6.9 months for irAE+ patients and 2.1 months for irAE- patients (P = .0004), and the median OS was 12.5 and 6.8 months, respectively (P = .007). Experiencing 1 or more irAEs remained associated with ORR (P = .03), PFS (P = .003), and OS (P = .004) in multivariate analyses. The association between development of irAEs and prolonged OS persisted in a 22-week landmark analysis (P = .049). The association between development of irAEs and favorable outcomes was verified in cohort 2.The development of irAEs was strongly associated with an ICI benefit, including overall response, PFS, and OS, in 2 separate cohorts of patients with recurrent/metastatic HNC." @default.
• W3200724207 created "2021-09-27" @default.
• W3200724207 creator A5008467612 @default.
• W3200724207 creator A5016275007 @default.
• W3200724207 creator A5020832184 @default.
• W3200724207 creator A5029916688 @default.
• W3200724207 creator A5048899616 @default.
• W3200724207 creator A5050018850 @default.
• W3200724207 creator A5056193789 @default.
• W3200724207 creator A5064621435 @default.
• W3200724207 creator A5071101610 @default.
• W3200724207 date "2021-09-21" @default.
• W3200724207 modified "2023-10-16" @default.
• W3200724207 title "Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors" @default.
• W3200724207 cites W1980825355 @default.
• W3200724207 cites W1988331425 @default.
• W3200724207 cites W2104885590 @default.
• W3200724207 cites W2105057287 @default.
• W3200724207 cites W2107283868 @default.
• W3200724207 cites W2107484016 @default.
• W3200724207 cites W2132916434 @default.
• W3200724207 cites W2155248311 @default.
• W3200724207 cites W2159648765 @default.
• W3200724207 cites W2179179825 @default.
• W3200724207 cites W2265285917 @default.
• W3200724207 cites W2289528730 @default.
• W3200724207 cites W2401455386 @default.
• W3200724207 cites W2510964327 @default.
• W3200724207 cites W2523194272 @default.
• W3200724207 cites W2529484692 @default.
• W3200724207 cites W2549481046 @default.
• W3200724207 cites W2664619167 @default.
• W3200724207 cites W2754877046 @default.
• W3200724207 cites W2759963646 @default.
• W3200724207 cites W2768499948 @default.
• W3200724207 cites W2770404972 @default.
• W3200724207 cites W2792492929 @default.
• W3200724207 cites W2810332541 @default.
• W3200724207 cites W2811088815 @default.
• W3200724207 cites W2896274372 @default.
• W3200724207 cites W2903486314 @default.
• W3200724207 cites W2904477283 @default.
• W3200724207 cites W2942674623 @default.
• W3200724207 cites W2945674342 @default.
• W3200724207 cites W2981366973 @default.
• W3200724207 cites W2986633517 @default.
• W3200724207 cites W2988124258 @default.
• W3200724207 cites W2999417355 @default.
• W3200724207 doi "https://doi.org/10.1002/cncr.33780" @default.
• W3200724207 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34547103" @default.
• W3200724207 hasPublicationYear "2021" @default.
• W3200724207 type Work @default.
• W3200724207 sameAs 3200724207 @default.
• W3200724207 citedByCount "20" @default.
• W3200724207 countsByYear W32007242072022 @default.
• W3200724207 countsByYear W32007242072023 @default.
• W3200724207 crossrefType "journal-article" @default.
• W3200724207 hasAuthorship W3200724207A5008467612 @default.
• W3200724207 hasAuthorship W3200724207A5016275007 @default.
• W3200724207 hasAuthorship W3200724207A5020832184 @default.
• W3200724207 hasAuthorship W3200724207A5029916688 @default.
• W3200724207 hasAuthorship W3200724207A5048899616 @default.
• W3200724207 hasAuthorship W3200724207A5050018850 @default.
• W3200724207 hasAuthorship W3200724207A5056193789 @default.
• W3200724207 hasAuthorship W3200724207A5064621435 @default.
• W3200724207 hasAuthorship W3200724207A5071101610 @default.
• W3200724207 hasBestOaLocation W32007242071 @default.
• W3200724207 hasConcept C121608353 @default.
• W3200724207 hasConcept C126322002 @default.
• W3200724207 hasConcept C141071460 @default.
• W3200724207 hasConcept C143998085 @default.
• W3200724207 hasConcept C144301174 @default.
• W3200724207 hasConcept C151956035 @default.
• W3200724207 hasConcept C197934379 @default.
• W3200724207 hasConcept C201903717 @default.
• W3200724207 hasConcept C2776530083 @default.
• W3200724207 hasConcept C2780739268 @default.
• W3200724207 hasConcept C3019894029 @default.
• W3200724207 hasConcept C38180746 @default.
• W3200724207 hasConcept C50382708 @default.
• W3200724207 hasConcept C71924100 @default.
• W3200724207 hasConcept C72563966 @default.
• W3200724207 hasConceptScore W3200724207C121608353 @default.
• W3200724207 hasConceptScore W3200724207C126322002 @default.
• W3200724207 hasConceptScore W3200724207C141071460 @default.
• W3200724207 hasConceptScore W3200724207C143998085 @default.
• W3200724207 hasConceptScore W3200724207C144301174 @default.
• W3200724207 hasConceptScore W3200724207C151956035 @default.
• W3200724207 hasConceptScore W3200724207C197934379 @default.
• W3200724207 hasConceptScore W3200724207C201903717 @default.
• W3200724207 hasConceptScore W3200724207C2776530083 @default.
• W3200724207 hasConceptScore W3200724207C2780739268 @default.
• W3200724207 hasConceptScore W3200724207C3019894029 @default.
• W3200724207 hasConceptScore W3200724207C38180746 @default.
• W3200724207 hasConceptScore W3200724207C50382708 @default.
• W3200724207 hasConceptScore W3200724207C71924100 @default.
• W3200724207 hasConceptScore W3200724207C72563966 @default.
• W3200724207 hasIssue "24" @default.

• next